CTMX
CytomX Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.71
+0.82%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- —
- P/S forward
- 30.65x
Trailing multiples
Trailing twelve months
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- 2.68x
- Price / sales
- 44.17x
- Price / cash flow
- -9.81x
Enterprise value
- Enterprise value
- $483.8M
- EV / sales
- 26.44x
- EV / EBITDA
- -6.18x
- EV / EBIT
- -5.55x
- Market cap
- $808.4M
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026